582313-57-3

Basic information

• Product Name: 4-Chloro-5-fluoro-7H-pyrrolo[2,3-d]-pyrimidine
• Synonyms: 4-Chloro-5-fluoro-7H-pyrrolo[2,3-d]-pyrimidine;6-Chloro-7-fluoro-7-deazapurine;7H-Pyrrolo[2,3-d]pyriMidine,4-chloro-5-fluoro-
• CAS NO: 582313-57-3
• Molecular Formula: C₆H₃ClFN₃
• Molecular Weight: 171.56
• Mol File: 582313-57-3.mol

Chemical Properties

• Appearance: /
• Density: 1.642±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 9.72±0.50(Predicted)
• CAS DataBase Reference: 4-Chloro-5-fluoro-7H-pyrrolo[2,3-d]-pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Chloro-5-fluoro-7H-pyrrolo[2,3-d]-pyrimidine(582313-57-3)
• EPA Substance Registry System: 4-Chloro-5-fluoro-7H-pyrrolo[2,3-d]-pyrimidine(582313-57-3)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 582313-57-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Development:
4-Chloro-5-fluoro-7H-pyrrolo[2,3-d]-pyrimidine is utilized as a key intermediate in the synthesis of pharmaceutical drugs. Its unique structure and properties make it a valuable component in the creation of new and effective medications.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 4-Chloro-5-fluoro-7H-pyrrolo[2,3-d]-pyrimidine is employed as a building block for the development of biologically active molecules. Its presence in various compounds contributes to their therapeutic potential, making it an essential tool for researchers in drug discovery and design.
Used in Cancer Treatment:
4-Chloro-5-fluoro-7H-pyrrolo[2,3-d]-pyrimidine has been investigated for its potential use in the treatment of cancer. Its incorporation into pharmaceutical compounds may contribute to the development of novel cancer therapies, offering new avenues for treatment and improving patient outcomes.
Used in the Synthesis of Biologically Active Molecules:
4-Chloro-5-fluoro-7H-pyrrolo[2,3-d]-pyrimidine is also used in the synthesis of biologically active molecules, which can have various applications in the medical and pharmaceutical industries. Its unique structure allows for the creation of molecules with specific biological activities, further expanding its utility in drug development.

Upstream product

• 22276-95-5 5-bromo-4-chloro-7H-pyrrolo[2,3-d]pyrimidine 
• 3680-69-1 4-chloro-1H-pyrrolo[2,3-d]pyrimidine 

Downstream Products

• 892389-00-3 4-chloro-5-fluoro-7-(2-C-methyl-3,5-di-O-(p-toluoyl)-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine 
• 1236281-72-3 tert-butyl 4-[4-(4-dimethylcarbamoyl-2-fluorophenylamino)-5-fluoropyrrolo[2,3-d]pyrimidin-7-yl]piperidine-1-carboxylate 
• 1365626-35-2 C₂₂H₂₂FN₅OS 
• 1236281-81-4 tert-butyl 4-[4-(2-chloro-4-mesylbenzoyl)-5-fluoropyrrolo[2,3-d]pyrimidin-7-yl]piperidine-1-carboxylate 
• 1236281-83-6 tert-butyl 4-[4-(2-chloro-α-hydroxy-4-mesylbenzyl)-5-fluoropyrrolo[2,3-d]pyrimidin-7-yl]piperidine-1-carboxylate 
• 1236281-82-5 tert-butyl 4-[4-(2-chloro-α,α-difluoro-4-mesylbenzyl)-5-fluoropyrrolo[2,3-d]pyrimidin-7-yl]piperidine-1-carboxylate 
• 1236281-74-5 tert-butyl 4-[5-fluoro-4-(2-fluoro-4-mesylphenoxy)pyrrolo[2,3-d]pyrimidin-7-yl]piperidine-1-carboxylate 
• 914377-18-7 C₂₆H₂₀ClF₂N₃O₅ 
• 914377-17-6 C₂₆H₂₀ClF₂N₃O₅ 
• 1040918-31-7 C₃₂H₃₅ClFN₃O₃Si 
• 892389-14-9 C₃₅H₂₉ClFN₃O₇ 
• 909782-95-2 N-(7-{5-[bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-3-fluoro-4-hydroxy-tetrahydro-furan-2-yl}-5-fluoro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-benzamide 
• 909782-93-0 N-[5-fluoro-7-(3-fluoro-4-hydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-benzamide 
• 952429-10-6 4-chloro-5-fluoro-7-(2,3,5-tri-O-benzoyl-β-L-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine 

Relevant articles and documents

Fluorine substituted adenosines as probes of nucleobase protonation in functional RNAs

Ionized nucleobases are required for folding, conformational switching, or catalysis in a number of functional RNAs. A common strategy to study these sites employs nucleoside analogues with perturbed pKa, but the interpretation of these studies

COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS

Disclosed are compounds active towards nuclear receptors, pharmaceutical compositions containing the compounds and use of the compounds in therapy.

SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5

The disclosure is directed to methods of treating disease using compounds of Formula (I).

Synthesis and anti-HBV activity of carbocyclic nucleoside hybrids with salient features of entecavir and aristeromycin

Modified carbocyclic nucleosides (4a-g) constituting 7-deazapurine, 4′-methyl, exocyclic double bond and 2′,3′-hydroxy were synthesized. NOE and X-ray studies of4cconfirmed the α-configuration of 4′-methyl. The anti-HBV assay demonstrated4e(IC50/sub

CYCLIC DINUCLEOTIDES AS STING AGONISTS

Disclosed are compounds, compositions and methods for treating of diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein B2,X2, R2a, R2b, R2c, Z-M-Y, Y1-M1Z1, B1, X1, R1a, R1b, R1c are as defined herein.

Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5)

The disclosure is directed to compounds of Formula I Pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.

SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS

Compounds of the general formula (I): processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.

New small molecule inhibitors of histone methyl transferase DOT1L with a nitrile as a non-traditional replacement for heavy halogen atoms

A number of new nucleoside derivatives are disclosed as inhibitors of DOT1L activity. SARs established that DOT1L inhibition could be achieved through incorporation of polar groups and small heterocycles at the 5-position (5, 6, 12) or by the application of alternative nitrogenous bases (18). Based on these results, CN-SAH (19) was identified as a potent and selective inhibitor of DOT1L activity where the polar 5-nitrile group was shown by crystallography to bind in the hydrophobic pocket of DOT1L. In addition, we show that a polar nitrile group can be used as a non-traditional replacement for heavy halogen atoms.

4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS

Provided is 4'-substituted nucleoside derivatives of Formula I and their use in the inhibition of HIV reverse transcriptase, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS and/or ARC.

Discovery and hit-to-lead optimization of pyrrolopyrimidines as potent, state-dependent Nav1.7 antagonists

Herein we describe the discovery, optimization, and structure-activity relationships of novel potent pyrrolopyrimidine Nav1.7 antagonists. Hit-to-lead SAR studies of the pyrrolopyrimidine core, head, and tail groups of the molecule led to the identification of pyrrolopyrimidine 48 as exceptionally potent Nav1.7 blocker with good selectivity over hERG and improved microsomal stability relative to our hit molecule and pyrazolopyrimidine 8 as a promising starting point for future optimization efforts.